Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract

Journal of Infectious Diseases

Volumn 180, Issue 2, 1999, Pages 384-390

  Donskey, Curtis J ^a   Hanrahan, Jennifer A ^a   Hutton, Rebecca A ^a   Rice, Louis B ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZTREONAM; CEFEPIME; CEFOTETAN; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; SODIUM CHLORIDE; SULTAMICILLIN; TIMENTIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; ENTEROCOCCUS FAECIUM; FECES ANALYSIS; GASTROINTESTINAL INFECTION; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DIGESTIVE SYSTEM; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS FAECIUM; FECES; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MICE; VANCOMYCIN;

EID: 0033502277     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314874     Document Type: Article

References (33)

1. 1. Finegold SM, Flora DJ, Attebery HR, Sutter VL. Fecal bacteriology of colonic polyp patients and control patients. Cancer Res 1975; 35:3407-17.
2. 2. Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990; 3:46-65.
3. 3. Chandrasekar PH, Smith BR, LeFrock JL, Carr B. Enterococcal superinfection and colonization with aztreonam therapy. Antimicrob Agents Chemother 1984; 26:280-2.
4. 4. Wells CL, Jechorek RP, Maddaus MA, Simmons RL. Effects of clindamycin and metronidazole on the intestinal colonization and translocation of enterococci in mice. Antimicrob Agents Chemother 1988; 32:1769-75.
5. 5. Vollaard EJ, Clasener HAL. Colonization resistance. Antimicrob Agents Chemother 1994; 38:409-14,
6. 6. Suppola JP, Volin L, Valtonen VV, Vaara M. Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies. Clin Infect Dis 1996; 23:694-7.
7. 7. Chirurgi VA, Oster SE, Goldberg AA, McCabe RE. Nosocomial acquisition of β-lactamase-negative, ampicillin-resistant enterococcus. Arch Intern Med 1992; 152:1457-61.
8. 8. Montecalvo MA, Horowitz H, Gedris C, et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994; 38:1363-7.
9. 9. Henning KJ, DeLancastre H, Fagan J, et al. Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 1996; 15:848-54.
10. 10. Yu V. Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic. Ann Intern Med 1981; 94: 784-5.
11. 11. Moellering RC Jr. Enterococcal infections in patients treated with moxalactam. Rev Infect Dis 1982; 4(Suppl);S708-11.
12. 12. Pallares R, Pujol M, Pena C, Ariza J, Martin R, Gudiol F. Cephalosporins as a risk factor for nosocomial Enterococcus faecalis bacteremia. Arch Intern Med 1993; 153:1581-6.
13. 13. Rice LB. The theoretical origin of vancomycin-resistant enterococci. Clin Microbiol Newslett 1995; 17:189-92.
14. 14. Whitman MS, Pitsakis PG, DeJesus E, Osborne AJ, Levison ME, Johnson CC. Gastrointestinal tract colonization with vancomycin-resistant Enterococcus faecium in an animal model. Antimicrob Agents Chemother 1996; 40:1526-30.
15. 15. van der Auwera P, Pensart N, Korten V, Murray BE, Leclercq R. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 1996; 173:1129-36.
16. 16. Moreno F, Grota P, Crisp C, et al. Clinical and molecular epidemiology of vancomycin-resistant Enterococcus faecium during its emergence in a city in southern Texas. Clin Infect Dis 1995; 21:1234-7.
17. 17. Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996; 23:767-72,
18. 18. Livomese LLJ, Dias S, Samel C. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992; 117:112-6.
19. 19. Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995; 20:1126-33.
20. 20. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998; 26:1127-33.
21. 21. Boyce JM. Vancomycin-resistant enterococcus: detection, epidemiology and control measures. Infect Dis Clin North Am 1997; 11:367-84.
22. 22. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996; 23:1020-5.
23. 23. Morris JG, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. Ann Intern Med 1995; 123:250-9.
24. 24. Donsky CJ, Schreiber J, Jacobs, MR, et al. A polyclonal outbreak of predominantly vanB vancomycin-resistant enterococci in Northeast Ohio. Clin Infect Dis, in press.
25. 25. Carias LL, Rudin SD, Donskey CJ, Rice LB. Genetic linkage and co-transfer of a novel, vanB-encoding transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecium isolate. J Bacteriol 1998; 180:4426-34.
26. 26. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Wayne, PA: NCCLS, 1993:M7-A3
27. 27. Murray BE. Editorial response: what can we do about vancomycin-resistant enterococci? Clin Infect Dis 1995; 20:1134-6.
28. 28. Edlund C, Barkholt L, Olsson-Liljequist B, Nord CE. Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin Infect Dis 1997; 25:729-32.
29. 29. Geraci JE, Heilman FR, Nichols DR, Wellman WE, Ross GT. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Proc Staff Meet Mayo Clin 1956; 31:564-82.
30. 30. Taylor EW, Poxon V, Alexander-Williams J, Jackson D. Biliary excretion of piperacillin. J Int Med Res 1983; 11:28-31.
31. 31. Bodey GP, Fainstein V, Garcia I, Rosenbaum B, Wong Y. Effect of broad-spectrum cephalosporins on the microbial flora of recipients. J Infect Dis 1983; 148:892-7.
32. 32. Wilson KH. The microccology of Clostridium difficile. Clin Infect Dis 1993; 16(Suppl 4):S214-8.
33. 33. van Ogtrop ML, Guiot HFL, Mattie H, van Furth R. Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins. Antimicrob Agents Chemother 1991; 35:976-82.